Article
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
Molecular pharmacology - 1 Jan 1993
Balzarini J, Velazquez S, San-Felix A, Karlsson A, Perez-Perez M J, Camarasa M J, De Clercq E
Abstract excerpt
The [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'- spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) derivatives of N1-methylhypoxanthine with linkage to the TSAO moiety through the N9 or N7 atom of the hypoxanthine ring (designated TSAO-m1Hx and 7-TSAO-m1Hx, respectively...
Topics
- Amino Acid Sequence
- Antiviral Agents
- Base Sequence
- Drug Resistance
- HIV Reverse Transcriptase
- HIV-1
- Humans
- Hypoxanthines
- Molecular Sequence Data
- Mutation
- RNA-Directed DNA Polymerase
- Spiro Compounds
- Structure-Activity Relationship